The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses
暂无分享,去创建一个
[1] Zining Wang,et al. Advances in mRNA vaccines , 2022, International Review of Cell and Molecular Biology.
[2] A. Maurya,et al. Identification of Severe Acute Respiratory Syndrome Coronavirus‐2 inhibitors through in silico structure‐based virtual screening and molecular interaction studies , 2021, Journal of molecular recognition : JMR.
[3] A. Khalafalla. MERS-CoV Infection , 2021, Infectious Diseases of Dromedary Camels.
[4] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[5] H. Feldmann,et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.
[6] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[7] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[8] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[9] P. Vollmar,et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.
[10] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[11] Z. Memish,et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.
[12] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.
[13] T. Pierson,et al. Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice. , 2019, The Journal of infectious diseases.
[14] R. Baric,et al. Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance , 2019, Journal of Virology.
[15] Barney S. Graham,et al. Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD , 2019, Cell Reports.
[16] David K. Meyerholz,et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. , 2019, The Journal of clinical investigation.
[17] D. Veesler,et al. Structural insights into coronavirus entry , 2019, Advances in Virus Research.
[18] W. Tan,et al. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus , 2019, Front. Microbiol..
[19] D. Weiner,et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial , 2019, The Lancet Infectious Diseases.
[20] S. S. Sohrab,et al. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model , 2019, The Journal of infectious diseases.
[21] A. Lambropoulos,et al. The Role of TLR4 Asp299Gly and TLR4 Thr399Ile Polymorphisms in the Pathogenesis of Urinary Tract Infections: First Evaluation in Infants and Children of Greek Origin , 2019, Journal of immunology research.
[22] M. Gale,et al. Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity , 2019, Journal of Virology.
[23] M. Hemida,et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development , 2019, Journal of immunology research.
[24] Lu Lu,et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike , 2019, Science Advances.
[25] Hu Shan,et al. Advances in mRNA Vaccines for Infectious Diseases , 2019, Front. Immunol..
[26] N. Petrovsky,et al. Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas , 2019, Viruses.
[27] Gheyath K Nasrallah,et al. Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar , 2019, Journal of immunology research.
[28] N. Pedersen,et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis , 2019, Journal of feline medicine and surgery.
[29] Christina Mayer,et al. Standardized, Scalable, and Timely Flexible Adeno-Associated Virus Vector Production Using Frozen High-Density HEK-293 Cell Stocks and CELLdiscs , 2019, Human gene therapy methods.
[30] A. Walls,et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.
[31] H. Feldmann,et al. Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset , 2019, Antiviral Research.
[32] Dong Yang,et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target , 2019, Nature Communications.
[33] Linqi Zhang,et al. Antibodies and vaccines against Middle East respiratory syndrome coronavirus , 2019, Emerging microbes & infections.
[34] Vineet D. Menachery,et al. Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism , 2019, Viruses.
[35] J. Joh,et al. Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] N. Ahmeda. Diagnostic delays in Middle East respiratory syndrome coronavirus patients and health systems , 2019 .
[37] B. Graham,et al. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization , 2018, Journal of Virology.
[38] Jinquan Luo,et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin , 2018, Science.
[39] R. Baric,et al. Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform , 2018, Communications Biology.
[40] M. Müller,et al. Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience , 2018, Antiviral therapy.
[41] R. Baric,et al. Giving the Genes a Shuffle: Using Natural Variation to Understand Host Genetic Contributions to Viral Infections , 2018, Trends in Genetics.
[42] J. Segalés,et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection , 2018, Science Advances.
[43] W. Kamitani,et al. Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells , 2018, Journal of Virology.
[44] Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines , 2018, Journal of Virology.
[45] Yufei Wang,et al. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV , 2018, Journal of Virology.
[46] Steffen Prüfer,et al. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model , 2018, Virology.
[47] R. Plemper,et al. Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses , 2018, Antimicrobial Agents and Chemotherapy.
[48] H. Feldmann,et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets , 2018, Antiviral Research.
[49] M. Schubert,et al. A New Family of Capsule Polymerases Generates Teichoic Acid-Like Capsule Polymers in Gram-Negative Pathogens , 2018, mBio.
[50] Jun Chang,et al. Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles , 2018, Front. Immunol..
[51] HIV latency reversing agents act through Tat post translational modifications , 2018, Retrovirology.
[52] William F. Kaemmerer,et al. How will the field of gene therapy survive its success? , 2018, Bioengineering & translational medicine.
[53] N. Pedersen,et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies , 2018, Veterinary Microbiology.
[54] Fang Li,et al. Discovery of Novel Bat Coronaviruses in South China That Use the Same Receptor as Middle East Respiratory Syndrome Coronavirus , 2018, Journal of Virology.
[55] Wenling Wang,et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus , 2018, Emerging Microbes & Infections.
[56] I. Morrissey,et al. Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae , 2018, Antimicrobial Agents and Chemotherapy.
[57] Robert J. Fischer,et al. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape , 2018, Journal of Virology.
[58] Xiaotao Lu,et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.
[59] A. Cianferoni. T Cell Responses , 2018 .
[60] Kevin S. Naceanceno,et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen , 2018, Vaccine.
[61] G. Ronzitti,et al. Emerging Issues in AAV-Mediated In Vivo Gene Therapy , 2017, Molecular therapy. Methods & clinical development.
[62] G. Whittaker,et al. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells , 2017, Virology.
[63] Clemens Vonrhein,et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA , 2017, Proceedings of the National Academy of Sciences.
[64] E. Frolova,et al. β-d-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome , 2017, Journal of Virology.
[65] T. Mak,et al. Tumor Necrosis Factor-Mediated Survival of CD169+ Cells Promotes Immune Activation during Vesicular Stomatitis Virus Infection , 2017, Journal of Virology.
[66] Lisa E. Gralinski,et al. Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis , 2017, mSphere.
[67] Robert J. Fischer,et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model , 2017, npj Vaccines.
[68] Barney S. Graham,et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.
[69] P. T. Ten Eyck,et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses , 2017, Science Immunology.
[70] Christopher McCabe,et al. Marketing of unproven stem cell–based interventions: A call to action , 2017, Science Translational Medicine.
[71] W. Strohl,et al. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy , 2017, BioDrugs.
[72] Lisa E. Gralinski,et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.
[73] T. Harford,et al. Ongoing developments in RSV prophylaxis: a clinician's analysis. , 2017, Current opinion in virology.
[74] A. Hill,et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice , 2017, Vaccine.
[75] M. Agbandje-McKenna,et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion , 2017, Proceedings of the National Academy of Sciences.
[76] Jianmin Wang,et al. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset , 2017, The Journal of infectious diseases.
[77] Yi Shi,et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.
[78] D. Dimitrov,et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets , 2017, Antiviral Research.
[79] P. T. Ten Eyck,et al. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection , 2017, The Journal of Immunology.
[80] Yufei Wang,et al. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection , 2017, Human vaccines & immunotherapeutics.
[81] A. Abbas,et al. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein , 2017, Scientific Reports.
[82] Jincun Zhao,et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice , 2017, Vaccine.
[83] Justin M. Richner,et al. Modified mRNA Vaccines Protect against Zika Virus Infection , 2017, Cell.
[84] A. Arvey,et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.
[85] M. Frieman,et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection , 2017, Vaccine.
[86] Jiun-Jie Shie,et al. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors , 2017, Antiviral Research.
[87] W. Wentao,et al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma , 2017, Scientific Reports.
[88] Christina A. Cuomo,et al. The Case for Adopting the “Species Complex” Nomenclature for the Etiologic Agents of Cryptococcosis , 2017, mSphere.
[89] G. Wong,et al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice , 2016, Antiviral Research.
[90] Bart L. Haagmans,et al. MERS-coronavirus: From discovery to intervention , 2016, One Health.
[91] G. Gao,et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection , 2016, Vaccine.
[92] Hualei Wang,et al. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques , 2016, Oncotarget.
[93] J. Brewer,et al. Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity , 2017, npj Vaccines.
[94] G. Wong,et al. Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection. , 2016, The Journal of infectious diseases.
[95] B. Gowen,et al. Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir , 2016, Journal of Virology.
[96] P. Jahrling,et al. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus , 2016, Journal of Virology.
[97] Z. Memish,et al. Viral shedding and antibody response in 37 patients with MERS-coronavirus infection , 2016 .
[98] Yufei Wang,et al. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.
[99] Yufei Wang,et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection , 2016, Virology.
[100] Fang Li,et al. Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.
[101] A. Tamin,et al. Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.
[102] D. Fisher,et al. A review of treatment modalities for Middle East Respiratory Syndrome , 2016, The Journal of antimicrobial chemotherapy.
[103] F. Hayden,et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia , 2016, Emerging infectious diseases.
[104] N. Petrovsky. SARS coronavirus infections of the lower respiratory tract and their prevention , 2016, The Microbiology of Respiratory System Infections.
[105] J. Tam,et al. Human Coronaviruses: A Review of Virus–Host Interactions , 2016, Diseases.
[106] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[107] Yufei Wang,et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection , 2016, Antiviral Research.
[108] Guangdi Li,et al. Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.
[109] Krishna Shankara Narayanan,et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.
[110] R. Baric,et al. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.
[111] Bernd W. Brandt,et al. Corrigendum: Intrinsic challenges in ancient microbiome reconstruction using 16S rRNA gene amplification , 2016, Scientific Reports.
[112] A. Lanzavecchia,et al. Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome , 2016, Journal of Infection and Public Health.
[113] G. Whittaker,et al. Fusion of Enveloped Viruses in Endosomes , 2016, Traffic.
[114] S. Perlman,et al. Middle East respiratory syndrome vaccines , 2016, International Journal of Infectious Diseases.
[115] N. Sardesai,et al. A synthetic consensus anti-Spike protein DNA vaccine induces protective immunity against Middle East Respiratory Syndrome Coronavirus in non-human primates , 2016, International Journal of Infectious Diseases.
[116] S. Kaufmann,et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects , 2016, The Lancet Infectious Diseases.
[117] Lisa E. Gralinski,et al. SARS-like WIV1-CoV poised for human emergence , 2016, Proceedings of the National Academy of Sciences.
[118] D. Dimitrov,et al. Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection , 2016, The Journal of infectious diseases.
[119] Barney S. Graham,et al. Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.
[120] Alimuddin Zumla,et al. Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.
[121] David K. Meyerholz,et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.
[122] V. Nene,et al. Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever , 2016, Scientific Reports.
[123] Ulas Bagci,et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 , 2016, Virology.
[124] D. Sautereau,et al. Ribavirin: Past, present and future. , 2016, World journal of hepatology.
[125] J. Segalés,et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels , 2016, Science.
[126] E. Won,et al. Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome , 2015, Antiviral therapy.
[127] Z. Memish,et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[128] S. Perlman,et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus , 2015, Cellular and Molecular Immunology.
[129] V. Volchkov,et al. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication , 2015, Viruses.
[130] Lisa E. Gralinski,et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.
[131] C. Burch,et al. Coronavirus Host Range Expansion and Middle East Respiratory Syndrome Coronavirus Emergence: Biochemical Mechanisms and Evolutionary Perspectives. , 2015, Annual review of virology.
[132] Shibo Jiang,et al. Middle East respiratory syndrome: current status and future prospects for vaccine development , 2015, Expert opinion on biological therapy.
[133] K. Yuen,et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein , 2015, Cell Research.
[134] D. Dimitrov,et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody , 2015, Nature Communications.
[135] H. Eldin,et al. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform , 2015, Journal of Virology.
[136] N. Sardesai,et al. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates , 2015, Science Translational Medicine.
[137] G. Gao,et al. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge , 2015, EBioMedicine.
[138] Malik Peiris,et al. Middle East respiratory syndrome , 2015, The Lancet.
[139] Ulas Bagci,et al. Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.
[140] R. Baric,et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.
[141] Jian-Piao Cai,et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.
[142] G. Yancopoulos,et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.
[143] Lu Lu,et al. Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection , 2015, The Journal of infectious diseases.
[144] Yuejin Wu,et al. Correction: Corrigendum: The mitochondrial uniporter controls fight or flight heart rate increases , 2015, Nature Communications.
[145] D. Hui,et al. Middle East respiratory syndrome , 2015, The Lancet.
[146] G. Sutter,et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.
[147] A. Asokan,et al. Strategies to circumvent humoral immunity to adeno-associated viral vectors , 2015, Expert opinion on biological therapy.
[148] B. Graham,et al. History of passive antibody administration for prevention and treatment of infectious diseases , 2015, Current opinion in HIV and AIDS.
[149] W. Tan,et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus , 2015, Immunology.
[150] F. Farahat,et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study , 2015, The Journal of antimicrobial chemotherapy.
[151] Shibo Jiang,et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus , 2015, Human vaccines & immunotherapeutics.
[152] Jincun Zhao,et al. Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection , 2015, Journal of Virology.
[153] Lisa E. Gralinski,et al. Molecular pathology of emerging coronavirus infections , 2014, The Journal of pathology.
[154] T. Butt,et al. Ribavirin and Interferon-α2b as Primary and Preventive Treatment for Middle East Respiratory Syndrome Coronavirus: A Preliminary Report of Two Cases , 2014, Antiviral therapy.
[155] Gary R. Whittaker,et al. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis , 2014, Virus Research.
[156] M. Müller,et al. Inhibition of Proprotein Convertases Abrogates Processing of the Middle Eastern Respiratory Syndrome Coronavirus Spike Protein in Infected Cells but Does Not Reduce Viral Infectivity , 2014, Journal of Infectious Diseases.
[157] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[158] M. Kandeel. Bioinformatics analysis of the recent MERS-CoV with special reference to the virus-encoded Spike protein , 2015 .
[159] S. Kanj,et al. Emergence of MERS-CoV in the Middle East: Origins, Transmission, Treatment, and Perspectives , 2014, PLoS pathogens.
[160] G. Gao,et al. Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen , 2014, PloS one.
[161] K. Benjamin,et al. Engineering Acetyl Coenzyme A Supply: Functional Expression of a Bacterial Pyruvate Dehydrogenase Complex in the Cytosol of Saccharomyces cerevisiae , 2014, mBio.
[162] G. Whittaker,et al. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein , 2014, Proceedings of the National Academy of Sciences.
[163] Z. Memish,et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study , 2014, The Lancet Infectious Diseases.
[164] Shibo Jiang,et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.
[165] James M. Wilson,et al. Adeno-Associated Virus 9-Mediated Airway Expression of Antibody Protects Old and Immunodeficient Mice against Influenza Virus , 2014, Clinical and Vaccine Immunology.
[166] A. Gambotto,et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.
[167] S. Almalki,et al. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health , 2014, International journal of general medicine.
[168] Arun K. Ghosh,et al. Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance , 2014, Journal of Virology.
[169] K. Okuda,et al. Developments in Viral Vector-Based Vaccines , 2014, Vaccines.
[170] Jincun Zhao,et al. T cell-mediated immune response to respiratory coronaviruses , 2014, Immunologic Research.
[171] S. Morikawa,et al. Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine , 2014, Journal of Virology.
[172] T. Bestebroer,et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.
[173] D. Dimitrov,et al. Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies , 2014, Journal of Virology.
[174] K. Yuen,et al. Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.
[175] William B. Karesh,et al. Middle East Respiratory Syndrome Coronavirus Quasispecies That Include Homologues of Human Isolates Revealed through Whole-Genome Analysis and Virus Cultured from Dromedary Camels in Saudi Arabia , 2014, mBio.
[176] R. Baric,et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.
[177] Shibo Jiang,et al. Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.
[178] M. Frieman,et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.
[179] Shibo Jiang,et al. A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein , 2014, Journal of Virology.
[180] G. Olinger,et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. , 2014, The Journal of general virology.
[181] R. Fouchier,et al. MERS: emergence of a novel human coronavirus , 2014, Current Opinion in Virology.
[182] Shibo Jiang,et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines , 2014, Vaccine.
[183] Alicia M Fry,et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. , 2014, The Lancet. Infectious diseases.
[184] C. D. dos Santos,et al. Biomarkers in acute respiratory distress syndrome , 2014, Current opinion in critical care.
[185] Lisa E. Gralinski,et al. Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2′-O-Methyltransferase Activity , 2014, Journal of Virology.
[186] Lu Lu,et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.
[187] Z. Memish,et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study , 2014, International Journal of Infectious Diseases.
[188] Lisa E. Gralinski,et al. Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses , 2013, The Journal of infectious diseases.
[189] S. Morikawa,et al. Effects of Toll-like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c 1 , 2014 .
[190] T. Butt,et al. Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia , 2014, Annals of Saudi medicine.
[191] Shibo Jiang,et al. A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2013, PloS one.
[192] J. Chiorini,et al. The family Parvoviridae , 2013, Archives of Virology.
[193] K. To,et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.
[194] George F. Gao,et al. Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.
[195] M. Katze,et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.
[196] Z. Memish,et al. Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy , 2013, International Journal of Infectious Diseases.
[197] G. Sutter,et al. Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies , 2013, Journal of Virology.
[198] M. Vignuzzi,et al. Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics , 2013, PLoS pathogens.
[199] H. Broxmeyer,et al. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. , 2013, Blood.
[200] D. Baltimore,et al. Broad protection against influenza infection by vectored immunoprophylaxis in mice , 2013, Nature Biotechnology.
[201] G. Wong,et al. Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza , 2013, Science Translational Medicine.
[202] S. Ray,et al. Clinical Use of Colistin Induces Cross-Resistance to Host Antimicrobials in Acinetobacter baumannii , 2013, mBio.
[203] S. Sarafianos,et al. Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms , 2013, Journal of Virology.
[204] Ivan D. Rukhlenko,et al. Quantum-dot supercrystals for future nanophotonics , 2013, Scientific Reports.
[205] H. Feldmann,et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin , 2013, Scientific Reports.
[206] W. Lipkin,et al. Viral surveillance and discovery. , 2013, Current opinion in virology.
[207] J. Mackenzie,et al. Reservoirs and vectors of emerging viruses , 2013, Current Opinion in Virology.
[208] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[209] T. K. Cabeça,et al. Epidemiological and clinical features of human coronavirus infections among different subsets of patients , 2013, Influenza and other respiratory viruses.
[210] D. Schaffer,et al. Directed evolution of adeno-associated virus for enhanced gene delivery to pluripotent and adult neural stem cells , 2013 .
[211] R. Baric,et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease , 2012, Nature Medicine.
[212] Lisa Hensley,et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.
[213] A. Bertoletti,et al. Understanding the T cell immune response in SARS coronavirus infection , 2012, Emerging Microbes & Infections.
[214] X. Qiu,et al. Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.
[215] G. Whittaker,et al. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.
[216] S. Shea,et al. Adverse Metabolic Consequences in Humans of Prolonged Sleep Restriction Combined with Circadian Disruption , 2012, Science Translational Medicine.
[217] David Baltimore,et al. Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.
[218] B. Prabhakar,et al. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential , 2011, Reviews in medical virology.
[219] R. Baric,et al. SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission , 2011, Current Opinion in Virology.
[220] Lisa E. Gralinski,et al. A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.
[221] D. Barnard,et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV , 2011, Vaccine.
[222] Hong Yang,et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study , 2011, The Journal of Immunology.
[223] R. Baric,et al. Coronaviruses , 2011, RNA biology.
[224] J. Ward,et al. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. , 2010, Viral immunology.
[225] Jincun Zhao,et al. T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.
[226] Raul Andino,et al. Quasispecies Theory and the Behavior of RNA Viruses , 2010, PLoS pathogens.
[227] M. Heikenwalder,et al. Reversible Microbial Colonization of Germ-Free Mice Reveals the Dynamics of IgA Immune Responses , 2010, Science.
[228] Fulvio Reggiori,et al. Coronaviruses Hijack the LC3-I-Positive EDEMosomes, ER-Derived Vesicles Exporting Short-Lived ERAD Regulators, for Replication , 2010, Cell Host & Microbe.
[229] S. Plotkin. Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.
[230] Timothy B. Stockwell,et al. Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing , 2010, PLoS pathogens.
[231] Shibo Jiang,et al. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. , 2010, Viral immunology.
[232] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[233] J. Grieger,et al. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[234] P. Woo,et al. Coronavirus Diversity, Phylogeny and Interspecies Jumping , 2009, Experimental biology and medicine.
[235] E. Matteucci,et al. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. , 2009, Current medicinal chemistry.
[236] S. Perlman,et al. Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.
[237] G. Whittaker,et al. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.
[238] D. Schaffer,et al. Directed evolution of adeno-associated virus to an infectious respiratory virus , 2009, Proceedings of the National Academy of Sciences.
[239] C. Broder,et al. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses , 2009, Expert opinion on biological therapy.
[240] James M. Wilson,et al. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[241] J. Mascola,et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.
[242] R. Brunham,et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. , 2008, The Journal of general virology.
[243] B. Zheng,et al. Helicases as antiviral drug targets. , 2008, Hong Kong medical journal = Xianggang yi xue za zhi.
[244] R. Baric,et al. A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian Hamsters , 2008, Journal of Virology.
[245] R. Baric,et al. Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.
[246] K. Yuen,et al. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1 , 2008, The Journal of Immunology.
[247] C. Peters,et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV , 2007, Vaccine.
[248] Ralph Baric,et al. SARS coronavirus and innate immunity , 2007, Virus Research.
[249] Xiaotao Lu,et al. High Fidelity of Murine Hepatitis Virus Replication Is Decreased in nsp14 Exoribonuclease Mutants , 2007, Journal of Virology.
[250] D. Dimitrov,et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.
[251] D. Barnard,et al. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice , 2007, Vaccine.
[252] David Eidelberg,et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.
[253] Ali Danesh,et al. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome , 2007, Journal of Virology.
[254] G. Kobinger,et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques , 2007, Vaccine.
[255] Silke Stertz,et al. The intracellular sites of early replication and budding of SARS-coronavirus , 2007, Virology.
[256] M. Peiris,et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro , 2006, Vaccine.
[257] R. Johnston,et al. Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants , 2006, PLoS medicine.
[258] D. Barnard,et al. Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice , 2006, Antiviral chemistry & chemotherapy.
[259] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[260] J. Onderwater,et al. Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex , 2006, Journal of Virology.
[261] Kwok-Hung Chan,et al. Coronavirus HKU1 and Other Coronavirus Infections in Hong Kong , 2006, Journal of Clinical Microbiology.
[262] B. Berkhout,et al. Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle , 2006, Antimicrobial Agents and Chemotherapy.
[263] Jongdae Lee,et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin , 2006, Antiviral Research.
[264] J. Penninger,et al. Angiotensin-converting enzyme II in the heart and the kidney. , 2006, Circulation research.
[265] R. Brunham,et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. , 2006, The Journal of general virology.
[266] Joseph L. Goldstein,et al. Protein Sensors for Membrane Sterols , 2006, Cell.
[267] M. Reiter,et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses , 2005, Vaccine.
[268] D. A. Stein,et al. Inhibition and Escape of SARS-CoV Treated with Antisense Morpholino Oligomers , 2006, Advances in experimental medicine and biology.
[269] P. Woo,et al. Clinical and Molecular Epidemiological Features of Coronavirus HKU1–Associated Community-Acquired Pneumonia , 2005, The Journal of infectious diseases.
[270] Jonathan H. Epstein,et al. Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.
[271] S. Diamond,et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[272] B. Murphy,et al. SARS Vaccine Protective in Mice , 2005, Emerging infectious diseases.
[273] K. Subbarao,et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine , 2005, Virology.
[274] B. Moss,et al. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein , 2005, Virology.
[275] T. Greenough,et al. Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice , 2005, The Journal of infectious diseases.
[276] H. Doerr,et al. Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.
[277] Jingxin Cao,et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.
[278] John Bechill,et al. Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity , 2004, Journal of Virology.
[279] P. Hsueh,et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.
[280] Xiaodong Xiao,et al. Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor , 2004, Hypertension.
[281] Pan‐Chyr Yang,et al. Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)—6, IL-8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[282] B. Murphy,et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.
[283] Hsuan-Cheng Huang,et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[284] B. Murphy,et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[285] T. Kuiken,et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.
[286] B. Murphy,et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.
[287] S. Günther,et al. Evaluation of Advanced Reverse Transcription-PCR Assays and an Alternative PCR Target Region for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus , 2004, Journal of Clinical Microbiology.
[288] V. Wong,et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.
[289] B. Moss,et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[290] F. Aoki,et al. Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.
[291] Gary J. Nabel,et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.
[292] B. Lim,et al. Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs , 2004, Emerging infectious diseases.
[293] Guoping Zhao,et al. Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China , 2004, Science.
[294] Y. Guan,et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.
[295] Wenhui Li,et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[296] Ton de Jong,et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.
[297] D. Chong,et al. Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do? , 2004, American journal of epidemiology.
[298] M. Otto,et al. Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N4-Hydroxycytidine , 2004, Antiviral chemistry & chemotherapy.
[299] J. Dennis,et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.
[300] Xin Li,et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.
[301] L. Poon,et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .
[302] Y. Guan,et al. Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.
[303] R. Kotin,et al. Adeno-Associated Virus Type 5 (AAV5) but Not AAV2 Binds to the Apical Surfaces of Airway Epithelia and Facilitates Gene Transfer , 2000, Journal of Virology.
[304] J. Ziebuhr,et al. Virus-encoded proteinases and proteolytic processing in the Nidovirales. , 2000, The Journal of general virology.
[305] Lihan K. Yan,et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.
[306] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[307] J. Drake,et al. Mutation rates among RNA viruses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[308] K. Propert,et al. Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.
[309] R. Chanock,et al. SEROEPIDEMIOLOGIC STUDIES OF CORONAVIRUS INFECTION IN ADULTS AND CHILDREN1 , 1970, American journal of epidemiology.